Shkreli is accused of ripping off his former pharma company Retrophin to pay off hedge-fund investors he was accused of defrauding. » Read More
By: Rachel Cao
Shares of Bristol-Myers climbed as much as 4 percent after billionaire Carl Icahn reportedly took a stake in the company, according to Dow Jones. » Read More
Momenta says Pfizer, a key supplier for its multiple sclerosis drug, has received a warning letter from the Food and Drug Administration. » Read More
By: Trent Gillies
Former Aetna CEO Ron Williams weighs in on what changes could be ahead for the Affordable Care Act and consumers. » Read More
Retirees will pay more for this medical insurance program in the new year. Find out how much you'll pay.
"Most Americans hate their insurance and they hate the health-care system. It's unaffordable and it needs to be fixed," Aetna's Mark Bertolini says.
President-elect Donald Trump's proposal to overhaul Medicaid funding could force states to raise taxes or cut spending.
Whether Donald Trump repeals Obamacare or simply fixes it, either way, the system needs restructuring, Centene chief Michael Neidorff tells CNBC.
Valeant shares were down 22 percent on Tuesday, but Wells Fargo's David Maris says the company still has some time to right the ship.
Senior Research Analyst David Amsellem says, "We had never viewed the previous ranges as credible."
Valeant Pharmaceuticals reported an 11 percent fall in quarterly revenue due to faltering sales, and cut its full-year profit and revenue forecasts.
A U.S. Senate committee urged regulators to launch a probe into whether EpiPen maker Mylan broke the law by preventing schools from purchasing competing allergy treatments.
More than $125 million has been spent over an initiative to bar state agencies from paying more for drugs than the Veterans Affairs Department pays.
Just 4 percent of people can define all four terms that determine how much they would pay out of pocket for health services.
Drugmaker Mylan may have overcharged hospitals that serve significant numbers of poor people for lifesaving anti-allergy devices.
Pharmaceutical stocks have been under pressure, but certain companies are doing things right, former Medtronic CEO Bill George says.
The West Virginia attorney general says Mylan could be liable for more than the $465 million the company agreed to pay.
Anthem said sales of Obamacare plans have been disappointing to date, and the company could pull back its business in those plans in 2018.
The deal could include $8.5 billion in cash as well as future royalty payments for the embattled pharmaceutical company.
The Republican presidential nominee is hoping that stories about rising Obamacare rates will help him with voters next Tuesday.
Billionaire investor and Hillary Clinton-supporter Mark Cuban said that Donald Trump has no idea how Obamacare works.
Health care advocates are urging people to shop for 2017 coverage when the annual open enrollment period begins.
Valeant's former CEO and CFO are at the center of a U.S. criminal probe against the drugmaker over its ties to a specialty pharmacy.
Enrollment runs from Tuesday through Jan. 31. Most Americans must have some form of health coverage during 2017 or face a tax penalty.
Get the best of CNBC in your inbox